Nanovibronix, INC Schedule 13G passive stakes

Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.

Bank of America Corporation has filed an amendment to Schedule 13G, disclosing beneficial ownership of 14 shares, representing 0.0% of ENvue Medical, Inc.'s common stock.
Bank of America Corporation has disclosed a 21.5% beneficial ownership stake in ENvue Medical, Inc., holding 234,235 common shares, with a significant warning of potential future dilution.
Alpha Capital Anstalt has reported a 9.99% beneficial ownership stake in NanoVibronix Inc., holding 82,471 shares of common stock.
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a passive beneficial ownership of 4.99% in NanoVibronix, Inc.'s common stock as of March 31, 2025.
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a shared beneficial ownership of 349,284 common shares, representing 9.99% of NanoVibronix, Inc.